Table 1 Characteristics of the PCNSL patients examined in this study.

From: Differential expression of individual transcript variants of PD-1 and PD-L2 genes on Th-1/Th-2 status is guaranteed for prognosis prediction in PCNSL

Characteristics

N (%)

OSa (days)

Median (Min–Max)

Univariable

Multivariable

HRb (95% CIc)

P-value

HR (95% CI)

P-value

Total

31 (100)

765 (188-3611)

    

Gender

       Male

16 (51.61)

990 (169.8–6378)

1

NAh

1

NA

       Female

15 (48.38)

951 (273–3738)

0.453 (0.116–1.528)

0.203

0.592 (0.190–1.745)

0.592

Age: Median (Min–Max) 67 (31–85)

       Age < 60

12 (38.70)

994.5 (317.1–6378)

1

NA

1

NA

       Age > 60

19 (61.29)

936.9 (169.8–3738)

1.232 (0.494–3.317)

0.658

0.790 (0.181–3.202)

0.738

KPSd: Median (Min–Max) 60 (40–90)

       0–60

19 (61.29)

936.9 (169.8–317.1)

1

NA

1

NA

       70–100

12 (38.70)

1080 (317.1–6378)

0.426 (0.133–1.160)

0.097

0.241 (0.008–6.561)

0.3491

MSKCCe

       1 (Age < 50)

4 (14.81)

1515 (840–3330)

1

NA

1

NA

       2 (Age > 50, KPS > 70)

9 (29.03)

951 (317.1–6378)

1.1920 (0.254–8.360)

0.832

2.0524 (0.207–48.228)

0.559

       3 (Age > 50, KPS < 70)

18 (58.06)

948.45 (169.8–3171)

2.2253 (0.590–14.563)

0.261

0.9349 (0.109–20.664)

0.956

IELSGf

       0-1

6 (19.35)

2175 (317.1–6378)

1

NA

1

NA

       2-3

20 (64.51)

807.9 (169.8–3525)

2.7591 (0.819–12.820)

0.106

3.4288 (0.639–24.152)

0.155

       4-5

5 (16.12)

1429.2 (936.9–3171)

1.5136 (0.269–8.619)

0.623

0.8690 (0.077–11.912)

0.910

Chemotherapy

       Ionizing radiation

3 (9.67)

762 (169.8–775.8)

1

NA

1

NA

       Polychemotherapy

9 (29.03)

1429.2 (317.1–6378)

0.242 (0.054–1.251)

0.085

0.495 (0.046–4.339)

0.528

       HD-MTXg

19 (61.29)

969 (273–3525)

0.209 (0.057–0.989)

0.048*

0.244 (0.044–1.433)

0.113

  1. Note: aOS; overall survival, bHR; hazard ratio, cCI; confidence interval, dKPS; Karnofsky Performance score, eMSKCC; Memorial Sloan Kettering Cancer Center risk score, fIELSG; International Extranodal Lymphoma Study Group risk score, gHD-MTX; high-dose methotrexate; hNA; not applicable, *P < 0.05, statistically significant.
Back to article page